07:00 , Jun 15, 2015 |  BioCentury  |  Finance

Deerfield pays Tribute to Pozen

Deerfield is betting $300 million on the combination of a Canadian cardiovascular specialty pharma with a U.S. biotech that has new management, a late-stage cardio asset and a royalty stream. The firm is backing a...
07:00 , Apr 8, 2013 |  BioCentury  |  Finance

Company builder

Company builder Several months after Vatera Holdings became Rib-X Pharmaceuticals Inc. 's biggest backer, the firm has now installed a handpicked CEO and new commercial head. The moves suggest any plans for a public exit...
07:00 , Nov 1, 2010 |  BioCentury  |  Finance

Specialty Pearl

Specialty Pearl Specialty pharma-focused venture firm Vatera Healthcare Partners invested in its fourth portfolio company last month, leading a $69 million series C round for respiratory disease company Pearl Therapeutics Inc. Vatera was formed in...
07:00 , Sep 20, 2010 |  BC Week In Review  |  Company News

Kos, Purdue Research Foundation deal

KOSP, which develops cardiovascular therapeutics, exclusively licensed technology from the foundation related to gastric retention drug delivery technologies. Purdue will receive milestone payments and royalties on future sales. Kos Pharmaceuticals Inc. (KOSP), Miami, Fla.  ...
07:00 , Aug 2, 2010 |  BC Week In Review  |  Clinical News

Simcor Niacin/simvastatin regulatory update

FDA approved new dosage strengths of Abbott's Simcor, a fixed-dose combination of extended-release niacin and immediate-release simvastatin to manage cholesterol levels in patients with complex lipid disease when treatment with either agent alone was not...
08:00 , Dec 21, 2009 |  BC Week In Review  |  Clinical News

Simcor niacin/simvastatin regulatory update

Abbott submitted an sNDA to FDA for 500/40 and 1000/40 mg dosage strengths of Simcor niacin extended release/simvastatin to treat mixed dyslipidemia and hyperlipidemia. FDA approved 500/20, 750/20 and 1000/20 mg strengths of Simcor last...
07:00 , Aug 18, 2008 |  BC Week In Review  |  Company News

Cortria management update

Cortria Corp. , Boston, Mass.   Business: Metabolic, Cardiovascular   Hired: Gene Cefali as SVP of clinical pharmacology and formulation development, formerly VP of lead optimization at Kos Pharmaceuticals Inc. (now part of Abbott Laboratories...
08:00 , Feb 18, 2008 |  BC Week In Review  |  Clinical News

Simcor niacin/simvastatin regulatory update

FDA approved an NDA from Abbott for Simcor, a fixed-dose combination of extended-release Niaspan niacin and immediate-release simvastatin to manage cholesterol levels in patients with complex lipid disease when treatment with either agent alone was...
01:28 , Feb 16, 2008 |  BC Extra  |  Company News

FDA approves Abbott's Simcor

FDA approved an NDA from Abbott (NYSE:ABT) for Simcor , a fixed-dose combination of extended-release niacin and immediate-release simvastatin, to manage cholesterol levels in patients with complex lipid disease when treatment with either therapy alone...
08:00 , Dec 24, 2007 |  BC Week In Review  |  Company News

SkyePharma, Abbott deal

The partners amended a 2006 deal, giving ABT responsibility for the additional clinical work on Flutiform requested by FDA in a pre-NDA meeting in August (see BioCentury, Aug. 13). ABT received U.S. rights to market...